Evidence map›Paper›PMID 29156737›Full record

ArticleOncotarget2017

Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Kei Kawaguchi, Kentaro Igarashi, Shukuan Li, Qinghong Han, Yuying Tan, Tasuku Kiyuna, Kentaro Miyake, Takashi Murakami, Bartosz Chmielowski, Scott D Nelson and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  8. Interactions between Radiation and One-Carbon Metabolism.International journal of molecular sciences · 2022
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Tumor-targetingHeliyon · 2018
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Kei KawaguchiAntiCancer, Inc., San Diego, CA, USA.
Kentaro IgarashiAntiCancer, Inc., San Diego, CA, USA.
Shukuan LiAntiCancer, Inc., San Diego, CA, USA.
Qinghong HanAntiCancer, Inc., San Diego, CA, USA.
Yuying TanAntiCancer, Inc., San Diego, CA, USA.
Tasuku KiyunaAntiCancer, Inc., San Diego, CA, USA.
Kentaro MiyakeAntiCancer, Inc., San Diego, CA, USA.
Takashi MurakamiAntiCancer, Inc., San Diego, CA, USA.
Bartosz ChmielowskiDivision of Hematology-Oncology, University of California, Los Angeles, CA, USA.
Scott D NelsonDepartment of Pathology, University of California, Los Angeles, CA, USA.
Tara A RussellDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Sarah M DryDepartment of Pathology, University of California, Los Angeles, CA, USA.
Yunfeng LiDepartment of Pathology, University of California, Los Angeles, CA, USA.
Michiaki UnnoDepartment of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Robert M HoffmanAntiCancer, Inc., San Diego, CA, USA.
University of California, Los Angeles · USAntiCancer (United States) · USUniversity of California, San Diego · USTohoku University · JP

Funding

Establishment of a patient-like mouse models of soft-tissue sarcoma sub-typesR43CA213649 · NCI · ANTICANCER, INC. · PI HOFFMAN, ROBERT M · 2017 to 2017
$225k
NCI NIH HHS R43 CA213649
6 · The paper itself

Abstract

An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant methioninase (rMETase). The present study used a previously-established patient-derived orthotopic xenograft (PDOX) nude mouse model of BRAF V600E-mutant melanoma to determine the efficacy of rMETase in combination with a first-line melanoma drug, temozolomide (TEM). In the present study 40 melanoma PDOX mouse models were randomized into four groups of 10 mice each: untreated control (n=10); TEM (25 mg/kg, oral 14 consecutive days, n=10); rMETase (100 units, intraperitoneal 14 consecutive days, n=10); combination TEM + rMETase (TEM: 25 mg/kg, oral rMETase: 100 units, intraperitoneal 14 consecutive days, n=10). All treatments inhibited tumor growth compared to untreated control (TEM:

Indexed as

melanomametabolic targetingmethionine dependencerecombinant methioninasetemozolomide

Identifiers

PMID29156737
PMCPMC5689627
OpenAlexW2742450412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.